Trial Profile
A phase III study of Paclical in patients with first and second line breast cancer treatment
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Hetero Drugs
- 12 Sep 2018 New trial record
- 31 Aug 2018 This study is expected to start in 2018, as reported in an Oasmia Pharmaceutical media release.